---
title: "ONO Pharma says Taiwan approves Opdivo perioperative regimen for resectable NSCLC"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296309213.md"
description: "ONO Pharmaceutical's Taiwan unit received TFDA approval on August 19 for OPDIVO in resectable non-small cell lung cancer. The label covers a perioperative regimen including neoadjuvant OPDIVO with chemotherapy, surgery, and adjuvant OPDIVO monotherapy. This decision is based on CheckMate-77T trial results demonstrating improved event-free survival and higher pathologic response rates."
datetime: "2026-08-19T06:05:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296309213.md)
  - [en](https://longbridge.com/en/news/296309213.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296309213.md)
generator: "portal-rs"
---

# ONO Pharma says Taiwan approves Opdivo perioperative regimen for resectable NSCLC

-   ONO Pharmaceutical’s Taiwan unit secured TFDA clearance on Aug. 19 for OPDIVO in resectable non-small cell lung cancer. \* Label covers perioperative use: neoadjuvant OPDIVO with platinum-doublet chemotherapy, then surgery, then adjuvant OPDIVO monotherapy. \* Decision based on CheckMate-77T results showing improved event-free survival, with higher pathologic complete response and major pathologic response. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ONO Pharmaceutical Co. Ltd. published the original content used to generate this news brief on August 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [OPHLY.US](https://longbridge.com/en/quote/OPHLY.US.md)
- [4528.JP](https://longbridge.com/en/quote/4528.JP.md)

## Related News & Research

- [Ono’s Opdivo wins South Korea approval for resectable NSCLC regimen](https://longbridge.com/en/news/294781396.md)
- [Teva EVP Business Development Evan Lippman sells 18,600 shares for $680,291.28](https://longbridge.com/en/news/296394259.md)
- [Pacira BioSciences CMO Jonathan Slonin sells 3,040 shares for $70,619.20](https://longbridge.com/en/news/296271811.md)
- [How Eli Lilly’s Global Vault CRM Rollout At Veeva Systems (VEEV) Has Changed Its Investment Story](https://longbridge.com/en/news/296430987.md)
- [Corcept Chief Business Officer Gary Charles Robb sells 10,000 shares for $1.16 million](https://longbridge.com/en/news/296267228.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**